INTRODUCTION
============

By comparing gene expressions in normal and diseased cells, microarrays are used to identify diseased genes and targets for therapeutic drugs. However, the huge amount of data provided by cDNA microarray measurements must be explored in order to answer fundamental questions about gene functions and their interdependence \[[@B1]\], and hopefully to provide answers to questions like what is the type of the disease affecting the cells or which genes have strong influence on this disease. Questions like this lead to the study of gene classification problems.

Many factors may affect the results of the analysis. One of them is the huge number of genes included in the original dataset. Key issues that need to be addressed under such circumstances are the efficient selection of good predictive gene groups from datasets that are inherently noisy, and the development of new methodologies that can enhance the successful classification of these complex datasets.

For multiclass cancer classification and discovery, the performance of different discrimination methods including nearest-neighbor classifiers, linear discriminant analysis, classification trees, and bagging and boosting learning methods are compared in \[[@B2]\]. Moreover, this problem has been studied by using partial least squares \[[@B3]\], Bayesian probit regression \[[@B4]\], and iterative classification trees \[[@B5]\]. But multiclass cancer classification, combined with gene selection, has not been investigated intensively. In the process of multiclass classification with gene selection, where there is an operation of classification, there is an operation of gene selection, which is the focus in this paper.

In the past decade, a number of variable (or gene) selection methods used in two-class classification have been proposed, notably, the support vector machine (SVM) method \[[@B6]\], perceptron method \[[@B7]\], mutual-information-based selection method \[[@B8]\], Bayesian variable selection \[[@B2], [@B9], [@B10], [@B11], [@B12]\], minimum description length principle for model selection \[[@B13]\], voting technique \[[@B14]\], and so on. In \[[@B6]\], gene selection using recursive feature elimination based on SVM (SVM-RFE) is proposed. When used in two-class circumstances, it is demonstrated experimentally that the genes selected by these techniques yield better classification performance and are biologically relevant to cancer than the other methods mentioned in \[[@B6]\], such as feature ranking with correlation coefficients or sensitivity analysis. But its application in multiclass gene selection has not been seen for its expensive calculation burden. Thus, gene preselection is adopted to get over this shortcoming; SVM-RFE is a key gene selection method used in our study.

As a two-class classification method, SVMs\' remarkable robust performance with respect to sparse and noisy data makes them first choice in a number of applications. Its application in cancer diagnosis using gene profiles is referred to in \[[@B15], [@B16]\]. In the recent years, the binary SVM has been used as a component in many multiclass classification algorithms, such as binary classification tree and fuzzy SVM (FSVM). Certainly, these multiclass classification methods all have excellent performance, which benefit from their root in binary SVM and their own constructions. Accordingly, we propose two different constructed multiclass classifiers with gene selection: one is to use binary classification tree based on SVM (BCT-SVM) with gene selection while the other is FSVM with gene selection. In this paper, F test and SVM-RFE are used as our gene selection methods. Three groups of experiments are done, respectively, by using FSVM with SVM-RFE, BCT-SVM with SVM-RFE, and BCT-SVM with F test. Compared to the methods in \[[@B2], [@B3], [@B5]\], our proposed methods can find out which genes are the most important genes to affect certain types of cancer. In these experiments, with most of the strongest genes selected, the prediction error rate of our algorithms is extremely low, and FSVM with SVM-RFE shows the best performance of all.

The paper is organized as follows. Problem statement is given in "problem statement." BCT-SVM with gene selection is outlined in "binary classification tree based on SVM with gene" selection. FSVM with gene selection is described in "FSVM with gene selection." Experimental results on breast cancer data, small round blue-cell tumors data, and acute leukemia data are reported in "experimental results." Analysis and discussion are presented in "analysis and discussion." "Conclusion" concludes the paper.

PROBLEM STATEMENT
=================

Assume there are *K* classes of cancers. Let **w** = \[*w~1~*, . . ., *w~m~*\] denote the class labels of *m* samples, where *w~i~ = k* indicates the sample *i* being cancer *k*, where *k* = 1, . . ., *K*. Assume *x*~1~, . . ., *x*~n~ are *n* genes. Let *x~ij~* be the measurement of the expression level of the *j*th gene for the *i*th sample, where *j* = 1,2, . . ., *n*, **X** = \[*x~ij~*\]~*m,n*~, denotes the expression levels of all genes, that is, $$\mathbf{X} = \begin{bmatrix}
{\text{Gene}\, 1} & {\text{Gene}\, 2} & \cdots & {\text{Gene}\, n} \\
x_{11} & x_{12} & \cdots & x_{1n} \\
x_{12} & x_{22} & \cdots & x_{2n} \\
 \vdots & \vdots & \ddots & \vdots \\
x_{m1} & x_{m2} & \cdots & x_{mm} \\
\end{bmatrix}.\qquad\left( 1 \right)$$

In the two proposed methods, every sample is partitioned by a series of optimal hyperplanes. The optimal hyperplane means training data is maximally distant from the hyperplane itself, and the lowest classification error rate will be achieved when using this hyperplane to classify current training set. These hyperplanes can be modeled as $$\mathbf{\omega}_{st}\mathbf{X}_{i}^{T} + b_{st} = 0\qquad\left( 2 \right)$$ and the classification functions are defined as $f_{st}\left( X_{i}^{T} \right) = \omega_{st}X_{i}^{T} + b_{st}$, where *X~i~* denotes the *i*th row of matrix *X*; *s* and *t* mean two partitions which are separated by an optimal hyperplane, and what these partitions mean lies on the construction of multiclass classification algorithms; for example, if we use binary classification tree, *s* and *t* mean two halves separated in an internal node, which may be the root node or a common internal node; if we use FSVM, *s* and *t* mean two arbitrary classes in *K* classes. *ω~st~* is an *n*-dimensional weight vector; *b~st~* is a bias term.

SVM algorithm is used to determinate these optimal hyperplanes. SVM is a learning algorithm originally introduced by Vapnik \[[@B17], [@B18]\] and successively extended by many other researchers. SVMs can work in combination with the technique of "kernels" that automatically do a nonlinear mapping to a feature space so that SVM can settle the nonlinear separation problems. In SVM, a convex quadratic programming problem is solved and, finally, optimal solutions of *ω~st~* and *b~st~* are given. Detailed solution procedures are found in \[[@B17], [@B18]\].

Along with each binary classification using SVM, one operation of gene selection is done in advance. Specific gene selection methods used in our paper are described briefly in "experimental results." Here, gene selection is done before SVM trained means that when an SVM is trained or used for prediction, dimensionality reduction will be done on input data, *X~i~*, referred to as the strongest genes selected. We use function $Y_{i} = I\left( {\beta_{st}X_{i}^{T}} \right)$ to represent this procedure, where *β~st~* is an *n* × *n* matrix, in which only diagonal elements may be equal to 1 or 0; and all other elements are equal to 0; genes corresponding to the nonzero diagonal elements are important. *β~st~* is gotten by specific gene selection methods; function $I\left( \cdot \right)$ means to select all nonzero elements in the input vector to construct a new vector , for example, *I*(\[1 0 2\])^*T*^ = \[1 2^*T*^\]. So ([2](#eq2){ref-type="other"}) is rewritten as $$\mathbf{\beta}_{st}\mathbf{X}_{i}^{T} + b_{st} = 0,\qquad\mathbf{Y}_{i} = I{\left( {\mathbf{\beta}_{st}\mathbf{X}_{i}^{T}} \right)\qquad\left( 3 \right)}$$ and the classification functions are rewritten as $f_{st}\left( X_{i}^{T} \right) = \beta_{st}X_{i}^{T} + b_{st}$ accordingly.

In order to accelerate calculation rate, preselecting genes before the training of multiclass classifiers is adopted. Based on all above, we propose two different constructed multiclass classifiers with gene selection: (1) binary classification tree based on SVM with gene selection, and (2) FSVM with gene selection.

BINARY CLASSIFICATION TREE BASED ON SVM WITH GENE SELECTION
===========================================================

Binary classification tree is an important class of machine-learning algorithms for multiclass classification. We construct binary classification tree with SVM; for short, we call it BCT-SVM. In BCT-SVM, there are *K* − 1 internal nodes and *K* terminal nodes. When building the tree, the solution of ([3](#eq3){ref-type="other"}) is searched by SVM at each internal node to separate the data in the current node into the left children node and right children node with appointed gene selection method, which is mentioned in "experimental results". Which class or classes should be partitioned into the left (or right) children node is decided at each internal node by impurity reduction \[[@B19]\], which is used to find the optimal construction of the classifier. The partition scheme with largest impurity reduction (IR) is optimal. Here, we use Gini index as our IR measurement criterion, which is also used in classification and regression trees (CARTs) \[[@B20]\] as a measurement of class diversity. Denote as *M* the training dataset at the current node, as *M~L~* and *M~R~* the training datasets at the left and right children nodes, as *M~i~* sample set of class *i* in the training set, as *M~R.i~* and *M~L.i~* sample sets of class *i* of the training dataset at the left and right children nodes; and we use λ~Θ~ to denote the number of samples in dataset Θ; the current IR can be calculated as follows, in which *c* means the number of classes in the current node: $$\begin{array}{l}
{\text{IR}\left( M \right) = \frac{1}{\lambda_{M}\lambda_{M_{L}}}\sum\limits_{i = 1}^{c}\left( \lambda_{M_{L \cdot i}} \right)^{2} + \frac{1}{\lambda_{M}\lambda_{M_{R}}}\sum\limits_{i = 1}^{c}\left( \lambda_{M_{R \cdot i}} \right)^{2}} \\
{- \frac{1}{\lambda_{M^{2}}}\sum\limits_{i = 1}^{c}\left( \lambda_{M_{i}} \right)^{2}.} \\
\end{array}\qquad\left( 4 \right)$$ When the maximum of IR(*M*) is found out based on all potential combinations of classes in the current internal node, which part of data should be partitioned into the left children node is decided. For the details to construct the standard binary decision tree, we refer to \[[@B19], [@B20]\].

After this problem is solved, samples partitioned into the left children node are labeled with −1, and the others are labeled with 1, based on these measures, a binary SVM classifier with gene selection is trained using the data of the two current children nodes. As to gene selection, it is necessary because the cancer classification is a typical problem with small sample and large variables, and it will cause overfitting if we directly train the classifier with all genes; here, all gene selection methods based on two-class classfication could be used to construct *β~st~* in ([3](#eq3){ref-type="other"}). The process of building a whole tree is recursive, as seen in [Figure 1](#F1){ref-type="fig"}.

When the training data at a node cannot be split any further, that node is identified as a terminal node and what we get from decision function corresponds to the label for a particular class. Once the tree is built, we could predict the results of the samples with genes selected by this tree; trained SVM will bring them to a terminal node, which has its own label. In the process of building BCT-SVM, there are *K* − 1 operations of gene selection done. This is due to the construction of BCT-SVM, in which there are *K* − 1 SVMs.

FSVM WITH GENE SELECTION
========================

Other than BCT-SVM, FSVM has a pairwise construction, which means every hyperplane between two arbitrary classes should be searched using SVM with gene selection. These processes are modeled by ([3](#eq3){ref-type="other"}).

FSVM is a new method firstly proposed by Abe and Inoue in \[[@B21], [@B22]\]. It was proposed to deal with unclassifiable regions when using one versus the rest or pairwise classification method based on binary SVM for *n*(\> 2)-class problems. FSVM is an improved pairwise classification method with SVM; a fuzzy membership function is introduced into the decision function based on pairwise classification. For the data in the classifiable regions, FSVM gives out the same classification results as pairwise classification with SVM method and for the data in the unclassifiable regions, FSVM generates better classification results than the pairwise classification with SVM method. In the process of being trained, FSVM is the same as the pairwise classification method with SVM that is referred to in \[[@B23]\].

In order to describe our proposed algorithm clearly, we denote four input variables: the sample matrix **X**~0~ = {**x**~1~ ,**x**~2~, . . ., **x**~*k*~, . . ., **x**~*m*~}^*T*^, that is, **X**~0~ is a matrix composed of some columns of original training dataset **X**, which corresponds to preselected important genes; the class-label vector **y** = {*y~1~*, *y~2~*, . . ., *y~k~*, . . ., *y~m~*}^*T*^; the number of classes in training set *ν*; and the number of important genes used in gene selection *κ*. With these four input variables, the training process of FSVM with gene selection is expressed in ([Algorithm 1](#F2){ref-type="fig"}).

In [Algorithm 1](#F2){ref-type="fig"}, *υ* = *GeneSelection* (*μ, $\phi$, κ*) is realization of a specific binary gene selection algorithm, *υ* denotes the genes important for two specific draw-out classes and is used to construct *β~st~* in ([3](#eq3){ref-type="other"}), *SV MTrain*($\cdot$) is realization of binary SVM algorithm, *α* is a Lagrange multiplier vector, and *ϵ* is a bias term. *γ*, *alpha*, and *bias*are the output matrixes. *γ*is made up of all important genes selected, in which each row corresponds to a list of important genes selected between two specific classes. *alpha* is a matrix with each row corresponding to Lagrange multiplier vector by an SVM classifier trained between two specific classes, and *bias* is the vector made up of bias terms of these SVM classifiers.

In this process, we may see there are *K*(*K* − 1)/2 SVMs trained and *K*(*K* − 1)/2 gene selections executed. This means that many important genes relative to two specific classes of samples will be selected.

Based on the *K*(*K* − 1)/2 optimal hyperplanes and the strongest genes selected, decision function is constructed based on ([3](#eq3){ref-type="other"}). Define *f~st~*(*X~i~*) = −*f~ts~*(*X~i~*), (*s* ≠ *t*); the fuzzy membership function *m~st~*(*X~i~*) is introduced on the directions orthogonal to *f~st~*(*X~i~*) = 0 as $$m_{st}\left( \mathbf{X}_{i} \right) = \left\{ \begin{array}{l}
{1\mspace{54mu}\text{for}\quad f_{st}\left( \mathbf{X}_{i} \right) \geq 1,} \\
{f_{st}{\left( \mathbf{X}_{i} \right)\quad\text{otherwise}.}} \\
\end{array} \right.\qquad\left( 5 \right)$$ Using *m~st~*(*X~i~*)(*s* ≠ *t*, *s* = 1, . . ., *n*), the class *i* membership function of *X~i~* is defined as *m~s~*(*X~i~*) = min~*t=1,\ .\ .\ .,\ n*~*m~st~*(*X~i~*), which is equivalent to *m~s~*(*X~i~*) = min(1, min~*s≠t,t=1,\ .\ .\ .,\ n*~ *f~st~*(*X~i~*)); now an unknown sample *X~i~* is classified by *arg*max~*s=1,\ .\ .\ .,\ n*~*m~s~*(*X~i~*).

EXPERIMENTAL RESULTS
====================

F test and SVM-RFE are gene selection methods used in our experiments. In F test, the ratio $R\left( j \right) = \sum_{i = 1}^{m}{\left( {\sum_{k = 1}^{K}1_{\mathbf{\Omega}_{i} = k}} \right)\left( {{\overline{x}}_{kj} - {\overline{x}}_{j}} \right)^{2}}/\sum_{i = 1}^{m}{\left( {\sum_{k = 1}^{K}1_{\mathbf{\Omega}_{i} = k}} \right)\left( {x_{ij} - {\overline{x}}_{kj}} \right)^{2}},1 \leq j \leq n$, is used to select genes, in which ${\overline{x}}_{j}$ denotes the average expression level of gene *j* across all samples and ${\overline{x}}_{kj}$ denotes the average expression level of gene *j* across the samples belonging to class *k* where class *k* corresponds to {Ω~*i*~ = *k*}; and the indicator function **1~Ω~** is equal to one if event Ω is true and zero otherwise. Genes with bigger *R*(*j*) are selected. From the expression of *R*(*j*) , it can be seen F test could select genes among *l*(\>3) classes \[[@B14]\]. As to SVM-RFE, it is recursive feature elimination based on SVM. It is a circulation procedure for eliminating features combined with training an SVM classifier and, for each elimination operation, it consists of three steps: (1) train the SVM classifier, (2) compute the ranking criteria for all features, and (3) remove the feature with the smallest ranking scores, in which all ranking criteria are relative to the decision function of SVM. As a linear kernel SVM is used as a classifier between two specific classes *s* and *t*, the square of every element of weight vector *ω~st~* in ([2](#eq2){ref-type="other"}) is used as a score to evaluate the contribution of the corresponding genes. The genes with the smallest scores are eliminated. Details are referred to in \[[@B6]\]. To speed up the calculation, gene preselection is generally used. On every dataset we use the first important 200 genes are selected by F test before multiclass classifiers with gene selection are trained. Note that F test requires normality of the data to be efficient which is not always the case for gene expression data. That is the exact reason why we cannot only use F test to select genes. Since the *P* values of important genes are relatively low, that means the F test scores of important genes should be relatively high. Considering that the number of important genes is often among tens of genes, we preselect the number of genes as 200 according to our experience in order to avoid losing some important genes. In the next experiments, we will show this procedure works effectively.

Combining these two specific gene selection methods with the multiclass classification methods, we propose three algorithms: (1) BCT-SVM with F test, (2) BCT-SVM with SVM-RFE, and (3) FSVM with SVM-RFE. As mentioned in \[[@B4], [@B9]\], every algorithm is tested with cross-validation (leave-one-out) method based on top 5, top 10, and top 20 genes selected by their own gene selection methods.

Breast cancer dataset
---------------------

In our first experiment, we will focus on hereditary breast cancer data, which can be downloaded from the web page for the original paper \[[@B24]\]. In \[[@B24]\], cDNA microarrays are used in conjunction with classification algorithms to show the feasibility of using differences in global gene expression profiles to separate BRCA1 and BRCA2 mutation-positive breast cancers. Twenty-two breast tumor samples from 21 patients were examined: 7 BRCA1, 8 BRCA2, and 7 sporadic. There are 3226 genes for each tumor sample. We use our methods to classify BRCA1, BRCA2, and sporadic. The ratio data is truncated from below at 0.1 and above at 20.

[Table 1](#T1){ref-type="table"} lists the top 20 strongest genes selected by using our methods. (For reading purpose, sometimes instead of clone ID, we use the gene index number in the database \[[@B24]\].) The clone ID and the gene description of a typical column of the top 20 genes selected by SVM-RFE are listed in [Table 2](#T2){ref-type="table"}; more information about all selected genes corresponding to the list in [Table 1](#T1){ref-type="table"} could be found at <http://www.sensornet.cn/fxia/top_20_genes.zip>. It is seen that gene 1008 (keratin 8) is selected by all the three methods. This gene is also an important gene listed in \[[@B4], [@B7], [@B9]\]. Keratin 8 is a member of the cytokeratin family of genes. Cytokeratins are frequently used to identify breast cancer metastases by immunohistochemistry \[[@B24]\]. Gene 10 (phosphofructokinase, platelet) and gene 336 (transducer of ERBB2, 1) are also important genes listed in \[[@B7]\]. Gene 336 is selected by FSVM with SVM-RFE and BCT-SVM with SVM-RFE; gene 10 is selected by FSVM with SVM-RFE.

Using the top 5, 10, and 20 genes each for these three methods, the recognition accuracy is shown in [Table 3](#T3){ref-type="table"}. When using top 5 genes for classification, there is one error for BCT-SVM with F test and no error for the other two methods. When using top 10 and 20 genes, there is no error for all the three methods. Note that the performance of our methods is similar to that in \[[@B4]\], where the authors diagnosed the tumor types by using multinomial probit regression model with Bayesian gene selection. Using top 10 genes, they also got zero misclassification.

Small round blue-cell tumors
----------------------------

In this experiment, we consider the small round blue-cell tumors (SRBCTs) of childhood, which include neuroblastoma (NB), rhabdomyosarcoma (RMS), nonHodgkin lymphoma (NHL), and the Ewing sarcoma (EWS) in \[[@B25]\]. The dataset of the four cancers is composed of 2308 genes and 63 samples, where the NB has 12 samples; the RMS has 23 samples; the NHL has 8 samples, and the EMS has 20 samples. We use our methods to classify the four cancers. The ratio data is truncated from below at 0.01.

[Table 4](#T4){ref-type="table"} lists the top 20 strongest genes selected by using our methods. The clone ID and the gene description of a typical column of the top 20 genes selected by SVM-RFE are listed in [Table 5](#T5){ref-type="table"}; more information about all selected genes corresponding to the list in [Table 4](#T4){ref-type="table"} could be found at <http://www.sensornet.cn/fxia/top_20_genes.zip>. It is seen that gene 244 (clone ID 377461), gene 2050 (clone ID 295985), and gene 1389 (clone ID 770394) are selected by all the three methods, and these genes are also important genes listed in \[[@B25]\]. Gene 255 (clone ID 325182), gene 107 (clone ID 365826), and gene 1 (clone ID 21652, (catenin alpha 1)) selected by BCT-SVM with SVM-RFE and FSVM with SVM-RFE are also listed in \[[@B25]\] as important genes.

Using the top 5, 10, and 20 genes for these three methods each, the recognition accuracy is shown in [Table 6](#T6){ref-type="table"}. When using top 5 genes for classification, there is one error for BCT-SVM with F test and no error for the other two methods. When using top 10 and 20 genes, there is no error for all the three methods.

In \[[@B26]\], Yeo et al applied *k* nearest neighbor (kNN), weighted voting, and linear SVM in one-versus-rest fashion to this four-class problem and compared the performances of these methods when they are combined with several feature selection methods for each binary classification problem. Using top 5 genes, top 10 genes, or top 20 genes, kNN, weighted voting, or SVM combined with all the three feature selection methods, respectively, without rejection all have errors greater than or equal to 2. In \[[@B27]\], Lee et al used multicategory SVM with gene selection. Using top 20 genes, their recognition accuracy is also zero misclassification number.

Acute leukemia data
-------------------

We have also applied the proposed methods to the leukemia data of \[[@B14]\], which is available at <http://www.sensornet.cn/fxia/top_20_genes.zip>. The microarray data contains 7129 human genes, sampled from 72 cases of cancer, of which 38 are of type B cell ALL, 9 are of type T cell ALL, and 25 of type AML. The data is preprocessed as recommended in \[[@B2]\]: gene values are truncated from below at 100 and from above at 16 000; genes having the ratio of the maximum over the minimum less than 5 or the difference between the maximum and the minimum less than 500 are excluded; and finally the base-10 logarithm is applied to the 3571 remaining genes. Here we study the 38 samples in training set, which is composed of 19 B-cell ALL, 8 T-cell ALL, and 11 AML.

[Table 7](#T7){ref-type="table"} lists the top 20 strongest genes selected by using our methods. The clone ID and the gene description of a typical column of the top 20 genes selected by SVM-RFE are listed in [Table 8](#T8){ref-type="table"}; more information about all selected genes corresponding to the list in [Table 7](#T7){ref-type="table"} could be found at <http://www.sensornet.cn/fxia/top_20_genes.zip>. It is seen that gene 1882 (CST3 cystatin C (amyloid angiopathy and cerebral hemorrhage)), gene 4847 (zyxin), and gene 4342 (TCF7 transcription factor 7 (T cell specific)) are selected by all the three methods. In the three genes, the first two are the most important genes listed in many literatures. Gene 2288 (DF D component of complement (adipsin)) is another important gene having biological significance, which is selected by FSVM with SVM-RFE.

Using the top 5, 10, and 20 genes for these three methods each, the recognition accuracy is shown in [Table 9](#T9){ref-type="table"}. When using top 5 genes for classification, there is one error for FSVM with SVM-RFE, two errors for BCT-SVM with SVM-RFE and BCT-SVM with F test, respectively. When using top 10 genes for classification, there is no error for FSVM with SVM-RFE, two errors for BCT-SVM with SVM-RFE and four errors for BCT-SVM with F test. When using top 20 genes for classification, there is one error for FSVM with SVM-RFE, two errors for BCT-SVM with SVM-RFE and two errors for BCT-SVM with F test. Again note that the performance of our methods is similar to that in \[[@B4]\], where the authors diagnosed the tumor types by using multinomial probit regression model with Bayesian gene selection. Using top 10 genes, they also got zero misclassification.

ANALYSIS AND DISCUSSION
=======================

According to Tables [1](#T1){ref-type="table"}--[9](#T9){ref-type="table"}, there are many important genes selected by these three multiclass classification algorithms with gene selection. Based on these selected genes, the prediction error rate of these three algorithms is low.

By comparing the results of these three algorithms, we consider that FSVM with SVM-RFE algorithm generates the best results. BCT-SVM with SVM-RFE and BCT-SVM with F test have the same multiclass classification structure. The results of BCT-SVM with SVM-RFE are better than those of BCT-SVM with F test, because their gene selection methods are different; a better gene selection method combined with the same multiclass classification method will perform better. It means SVM-RFE is better than F test combined with multiclass classification methods; the results are similar to what is mentioned in \[[@B6]\], in which the two gene selection methods are combined with two-class classification methods.

FSVM with SVM-RFE and BCT-SVM with SVM-RFE have the same gene selection methods. The results of FSVM with SVM-RFE are better than those of BCT-SVM with SVM-RFE whether in gene selection or in recognition accuracy, because the constructions of their multiclass classification methods are different, which is explained in two aspects. (1) The genes selected by FSVM with SVM-RFE are more than those of BCT-SVM with SVM-REF. In FSVM there are *K*(*K* − 1)/2 operations of gene selection, but in BCT-SVM there are only *K* −1 operations of gene selection. An operation of gene selection between every two classes is done in FSVM with SVM-RFE; (2) FSVM is an improved pairwise classification method, in which the unclassifiable regions being in BCT-SVM are classified by FSVM\'s fuzzy membership function \[[@B21], [@B22]\]. So, FSVM with SVM-RFE is considered as the best of the three.

CONCLUSION
==========

In this paper, we have studied the problem of multiclass cancer classification with gene selection from gene expression data. We proposed two different new constructed classifiers with gene selection, which are FSVM with gene selection and BCT-SVM with gene selection. F test and SVM-RFE are used as our gene selection methods combined with multiclass classification methods. In our experiments, three algorithms (FSVM with SVM-RFE, BCT-SVM with SVM-RFE, and BCT-SVM with F test) are tested on three datasets (the real breast cancer data, the small round blue-cell tumors, and the acute leukemia data). The results of these three groups of experiments show that more important genes are selected by FSVM with SVM-RFE, and by these genes selected it shows higher prediction accuracy than the other two algorithms. Compared to some existing multiclass cancer classifiers with gene selection, FSVM based on SVM-RFE also performs very well. Finally, an explanation is provided on the experimental results of this study.

This work is supported by China 973 Program under Grant no 2002CB312200 and Center of Bioinformatics Program grant of Harvard Center of Neurodegeneration and Repair, Harvard University, Boston, USA.

Figures and Tables
==================

![Binary classification tree based on SVM with gene selection.](40604.fig.001){#F1}

![The FSVM with gene selection training algorithm.](40604.fig.002){#F2}

###### 

The index no of the strongest genes selected in hereditary breast cancer dataset.

  ---- ------------------- --------------------- ---------------------- ------ ------ ------ ------
  No   FSVM with SVM-RFE   BCT-SVM with F test   BCT-SVM with SVM-RFE                        
                                                                                             
  1    2                   3                     1                      2      1      2      
                                                                                             
  1    1008                1859                  422                    501    1148   750    1999
  2    955                 1008                  2886                   2984   838    860    3009
  3    1479                10                    343                    3104   1859   1008   158
  4    2870                336                   501                    422    272    422    2761
  5    538                 158                   92                     2977   1008   2804   247
  6    336                 1999                  3004                   2578   1179   1836   1859
  7    3154                247                   1709                   3010   1065   3004   1148
  8    2259                1446                  750                    2804   2423   420    838
  9    739                 739                   2299                   335    1999   1709   1628
  10   2893                1200                  341                    2456   2699   3065   1068
  11   816                 2886                  1836                   1116   1277   2977   819
  12   2804                2761                  219                    268    1068   585    1797
  13   1503                1658                  156                    750    963    1475   336
  14   585                 560                   2867                   2294   158    3217   2893
  15   1620                838                   3104                   156    609    501    2219
  16   1815                2300                  1412                   2299   1417   146    585
  17   3065                538                   3217                   2715   1190   343    1008
  18   3155                498                   2977                   2753   2219   1417   2886
  19   1288                809                   1612                   2979   560    2299   36
  20   2342                1092                  2804                   2428   247    2294   1446
  ---- ------------------- --------------------- ---------------------- ------ ------ ------ ------

###### 

A part of the strongest genes selected in hereditary breast cancer dataset (the first row of genes in [Table 1](#T1){ref-type="table"}).

  ------------------------------------- ---------- ---------- ---------------------------------------------------------------
  Rank                                  Index no   Clone ID   Gene description
                                                              
  1                                     1008       897781     Keratin 8
  2                                     955        950682     Phosphofructokinase, platelet
  3                                     1479       841641     Cyclin D1 (PRAD1: parathyroid adenomatosis 1)
  4                                     2870       82991      Phosphodiesterase I/nucleotide pyrophosphatase 1
  (homologous to mouse Ly-41 antigen)                         
  5                                     538        563598     Human GABA-A receptor *π* subunit mRNA, complete cds
  6                                     336        823940     Transducer of ERBB2, 1
  7                                     3154       135118     GATA-binding protein 3
  8                                     2259       814270     Polymyositis/scleroderma autoantigen 1 (75kd)
  9                                     739        214068     GATA-binding protein 3
  10                                    2893       32790      mutS (*E coli*) homolog 2 (colon cancer, nonpolyposis type 1)
  11                                    816        123926     Cathepsin K (pycnodysostosis)
  12                                    2804       51209      Protein phosphatase 1, catalytic subunit, beta isoform
  13                                    1503       838568     Cytochrome c oxidase subunit VIc
  14                                    585        293104     Phytanoyl-CoA hydroxylase (Refsum disease)
  15                                    1620       137638     ESTs
  16                                    1815       141959     *Homo sapiens* mRNA; cDNA DKFZp566J2446
  (from clone DKFZp566J2446)                                  
  17                                    3065       199381     ESTs
  18                                    3155       136769     TATA box binding protein (TBP)-associated factor,
  RNA polymerase II, A, 250kd                                 
  19                                    1288       564803     Forkhead (drosophila)-like 16
  20                                    2342       284592     Platelet-derived growth factor receptor, alpha polypeptide
  ------------------------------------- ---------- ---------- ---------------------------------------------------------------

###### 

Classifiers\' performance on hereditary breast cancer dataset by cross-validation (number of wrong classified samples in leave-one-out test).

  ----------------------- ------- -------- --------
  Classification method   Top 5   Top 10   Top 20
                                           
  FSVM with SVM-RFE       0       0        0
  BCT-SVM with F test     1       0        0
  BCT-SVM with SVM-RFE    0       0        0
  ----------------------- ------- -------- --------

###### 

The index no of the strongest genes selected in small round blue-cell tumors dataset.

  ---- ------------------- --------------------- ----------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  No   FSVM with SVM-RFE   BCT-SVM with F test   SVM-RFE SVM-RFE                                                           
                                                                                                                           
  1    2                   3                     4                 5      6      1      2      3      1      2      3      
                                                                                                                           
  1    246                 255                   1954              851    187    1601   1074   169    422    545    174    851
  2    1389                867                   1708              846    509    842    246    1055   1099   1389   1353   846
  3    851                 246                   1955              1915   2162   1955   1708   338    758    2050   842    1915
  4    1750                1389                  509               1601   107    255    1389   422    1387   1319   1884   1601
  5    107                 842                   2050              742    758    2046   1954   1738   761    1613   1003   742
  6    2198                2050                  545               1916   2046   1764   607    1353   123    1003   707    1916
  7    2050                365                   1389              2144   2198   509    1613   800    84     246    1955   2144
  8    2162                742                   2046              2198   2022   603    1645   714    1888   867    2046   2198
  9    607                 107                   348               1427   1606   707    1319   758    951    1954   255    1427
  10   1980                976                   129               1      169    174    566    910    1606   1645   169    1
  11   567                 1319                  566               1066   1      1353   368    2047   1914   1110   819    1066
  12   2022                1991                  246               867    1915   169    1327   2162   1634   368    509    867
  13   1626                819                   1207              788    788    1003   244    2227   867    129    166    788
  14   1916                251                   1003              153    1886   742    545    2049   783    348    1207   153
  15   544                 236                   368               1980   554    2203   1888   1884   2168   365    603    1980
  16   1645                1954                  1105              2199   1353   107    2050   1955   1601   107    796    2199
  17   1427                1708                  1158              783    338    719    430    1207   335    1708   1764   783
  18   1708                1084                  1645              1434   846    166    365    326    1084   187    719    1434
  19   2303                566                   1319              799    1884   1884   1772   796    836    1626   107    799
  20   256                 1110                  1799              1886   2235   1980   1298   230    849    1772   2203   1886
  ---- ------------------- --------------------- ----------------- ------ ------ ------ ------ ------ ------ ------ ------ ------

###### 

A part of the strongest genes selected in small round blue-cell tumors dataset (the first row of genes in [Table 4](#T4){ref-type="table"}).

  ---------------------------------------------------- ---------- ---------- --------------------------------------------------------
  Rank                                                 Index no   Clone ID   Gene description
                                                                             
  1                                                    246        377461     Caveolin 1, caveolae protein, 22kd
  2                                                    1389       770394     Fc fragment of IgG, receptor, transporter, alpha
  3                                                    851        563673     Antiquitin 1
  4                                                    1750       233721     Insulin-like growth factor binding protein 2 (36kd)
  5                                                    107        365826     Growth arrest-specific 1
  6                                                    2198       212542     *H sapiens* mRNA; cDNA DKFZp586J2118
  (from clone DKFZp586J2118)                                                 
  7                                                    2050       295985     ESTs
  8                                                    2162       308163     ESTs
  9                                                    607        811108     Thyroid hormone receptor interactor 6
  10                                                   1980       841641     Cyclin D1 (PRAD1: parathyroid adenomatosis 1)
  11                                                   567        768370     tissue inhibitor of metalloproteinase 3
  (Sorsby fundus dystrophy, pseudoinflammatory)                              
  12                                                   2022       204545     ESTs
  13                                                   1626       811000     Lectin, galactoside-binding, soluble, 3 binding
  protein (galectin 6 binding protein)                                       
  14                                                   1916       80109      Major histocompatibility complex, class II, DQ alpha 1
  15                                                   544        1416782    Creatine kinase, brain
  16                                                   1645       52076      Olfactomedinrelated ER localized protein
  17                                                   1427       504791     Glutathione S-transferase A4
  18                                                   1708       43733      Glycogenin 2
  19                                                   2303       782503     *H sapiens* clone 23716 mRNA sequence
  20                                                   256        154472     Fibroblast growth factor receptor 1
  (fms-related tyrosine kinase 2, Pfeiffer syndrome)                         
  ---------------------------------------------------- ---------- ---------- --------------------------------------------------------

###### 

Classifiers\' performance on small round blue-cell tumors dataset by cross-validation (number of wrong classified samples in leave-one-out test).

  ----------------------- ------- -------- --------
  Classification method   Top 5   Top 10   Top 20
                                           
  FSVM with SVM-RFE       0       0        0
  BCT-SVM with F test     1       0        0
  BCT-SVM with SVM-RFE    0       0        0
  ----------------------- ------- -------- --------

###### 

The index no of the strongest genes selected in acute leukemia dataset.

  ---- ------------------- --------------------- ---------------------- ------ ------ ------ ------
  No   FSVM with SVM-RFE   BCT-SVM with F test   BCT-SVM with SVM-RFE                        
                                                                                             
  1    2                   3                     1                      2      1      2      
                                                                                             
  1    6696                1882                  6606                   2335   4342   1882   4342
  2    6606                4680                  6696                   4680   4050   6696   4050
  3    4342                6201                  4680                   2642   1207   5552   5808
  4    1694                2288                  4342                   1882   6510   6378   1106
  5    1046                6200                  6789                   6225   4052   3847   3969
  6    1779                760                   4318                   4318   4055   5300   1046
  7    6200                2335                  1893                   5300   1106   2642   6606
  8    6180                758                   1694                   5554   1268   2402   6696
  9    6510                2642                  4379                   5688   4847   3332   2833
  10   1893                2402                  2215                   758    5543   1685   1268
  11   4050                6218                  3332                   4913   1046   4177   4847
  12   4379                6376                  3969                   4082   2833   6606   6510
  13   1268                6308                  6510                   6573   4357   3969   2215
  14   4375                1779                  2335                   6974   4375   6308   1834
  15   4847                6185                  6168                   6497   6041   760    4535
  16   6789                4082                  2010                   1078   6236   2335   1817
  17   2288                6378                  1106                   2995   6696   2010   4375
  18   1106                4847                  5300                   5442   1630   6573   5039
  19   2833                5300                  4082                   2215   6180   4586   4379
  20   6539                1685                  1046                   4177   4107   2215   5300
  ---- ------------------- --------------------- ---------------------- ------ ------ ------ ------

###### 

A part of the strongest genes selected in small round blue-cell tumors dataset (the second row of genes in [Table 4](#T4){ref-type="table"}).

  -------------------------------------------- ---------- ----------------------- --------------------------------------------------------------
  Rank                                         Index no   Gene accession number   Gene description
                                                                                  
  1                                            1882       M27891_at               CST3 cystatin C (amyloid angiopathy and cerebral hemorrhage)
  2                                            4680       X82240_rna1_at          TCL1 gene (T-cell leukemia) extracted from *H sapiens*
  mRNA for T-cell leukemia/lymphoma 1                                             
  3                                            6201       Y00787_s\_at            Interleukin-8 precursor
  4                                            2288       M84526_at               DF D component of complement (adipsin)
  5                                            6200       M28130_rna1_s\_at       Interleukin-8 (IL-8) gene
  6                                            760        D88422_at               Cystatin A
  7                                            2335       M89957_at               IGB immunoglobulin-associated beta (B29)
  8                                            758        D88270_at               GB DEF = (lambda) DNA for immunoglobin light chain
  9                                            2642       U05259_rna1_at          MEF2C MADS box transcription enhancer factor 2,
  polypeptide C (myocyte enhancer factor 2C)                                      
  10                                           2402       M96326_rna1_at          Azurocidin gene
  11                                           6218       M27783_s\_at            ELA2 Elastatse 2, neutrophil
  12                                           6376       M83652_s\_at            PFC properdin P factor, complement
  13                                           6308       M57731_s\_at            GRO2 GRO2 oncogene
  14                                           1779       M19507_at               MPO myeloperoxidase
  15                                           6185       X64072_s\_at            SELL leukocyte adhesion protein beta subunit
  16                                           4082       X05908_at               ANX1 annexin I (lipocortin I)
  17                                           6378       M83667_rna1_s\_at       NF-IL6-beta protein mRNA
  18                                           4847       X95735_at               Zyxin
  19                                           5300       L08895_at               MEF2C MADS box transcription enhancer factor 2,
  polypeptide C (myocyte enhancer factor 2C)                                      
  20                                           1685       M11722_at               Terminal transferase mRNA
  -------------------------------------------- ---------- ----------------------- --------------------------------------------------------------

###### 

Classifiers\' performance on acute leukemia dataset by cross-validation (number of wrong classified samples in leave-one-out test).

  ----------------------- ------- -------- --------
  Classification method   Top 5   Top 10   Top 20
                                           
  FSVM with SVM-RFE       1       0        1
  BCT-SVM with F test     2       4        2
  BCT-SVM with SVM-RFE    2       1        2
  ----------------------- ------- -------- --------
